Skip to main content
Psychedex
Article

2-Fluorodeschloroketamine Facts

Dissociative; Arylcyclohexylamine; NMDA receptor antagonist

Description

2-FDCK (2-fluorodeschloroketamine) — also known as fluoroketamine — is a synthetic dissociative of the arylcyclohexylamine class.[1] It blocks glutamate signaling in the brain,[2] producing the detachment from body and environment that defines dissociative experiences.

Subjective effects include dissociation, cognitive softening, perceptual distortion, time alteration, and analgesia. The experience builds gradually — a warm, layered disconnection from body and environment, more gentle in onset than Ketamine, though deep hole states remain possible at higher doses.

2-FDCK produces clinical dependence with chronic daily use,[3] and its toxicity is shaped primarily by cardiovascular stimulation and respiratory risk. Every documented fatality involved polydrug combinations — other depressants compound its sedating effects and can stop breathing entirely.[4][5]

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 5 mgLight10 – 25 mgCommon25 – 70 mgStrong70 – 100 mgHeavy100+ mg

Starts in 15 – 50 minLasts 2.5 – 5 hoursAfter-effects 2 – 4 hours

Body and dependence

Acute toxicity
Moderate
Chronic toxicity
Moderate
Physical dependence
Low
Psychological dependence
Moderate
Withdrawal
Mild
Compulsive redosing
Moderate

Tolerance

Builds
Moderate
Fully resets after
10 days
Carries over to
ketamine; deschloroketamine; methoxetamine; phencyclidine

Effectslikely at a common dose

Perception
Spatial disorientation; Ganzfeld effect; +21 possible, including Visual acuity suppression, Double vision, Vestibular distortion
Body
Motor control impairment; Pain suppression; +26 possible, including Dizziness, Nystagmus (eye wobbles), Heart rate perception changes
Thinking
Cognitive impairment; +25 possible, including Memory suppression, Decision impairment, Analysis suppression
Feeling
none likely · 6 possible, including Anxiety, Emotional lability, Paranoia
Self
Derealization; +8 possible, including Depersonalization, Communication suppression, Social disconnection
Time
Time alteration; +3 possible, including Temporal disorientation
Awareness
none likely · 2 possible

Who shouldn't take it

Absolute
Hypertension; Coronary artery disease; Respiratory compromise; Psychotic disorders; Pregnancy and breastfeeding; Concurrent CNS depressant use
Relative
Epilepsy; Urological conditions

Combinations63 recorded

Lethal (4)
Alcohol; GHB, GBL; Ibogaine; Tramadol
Dangerous (34)
Amphetamines; Antihistamines; Benzodiazepines; Benzodiazepines, Barbiturates; Buprenorphine, Kratom; Ephedrine, Pseudoephedrine; Naltrexone; NDRIs (Wellbutrin); NRIs; NSAIDs; Opioids; Stimulants; THC; Anticholinergics; Antipsychotics; Buspirone; Caffeine; Clonidine, Guanfacine; Dopamine agonists; Gabapentin, Pregabalin; GHB, Baclofen; Ketamine, DXM, PCP; Lithium; Local anesthetics; and 10 more, see full page
Caution (21)
See full page: psychedex.org/substances/2-fluorodeschloroketamine
Not graded (4)
Not listed never means safe.

Seek help immediately if

  • Severe disorientation; unable to move or speak (deep dissociation / "k-hole")
  • Complete loss of coordination — cannot stand or walk safely
  • Vomiting while incapacitated (choking / aspiration risk)
  • Very high blood pressure; fast heart rate
  • Slow or shallow breathing at high doses (especially mixed with depressants)
  • Unconsciousness; rarely, seizures

What to do

  1. Move them somewhere safe, away from stairs, water, roads, and sharp edges — they cannot protect themselves
  2. Place in the recovery position if vomiting or unconscious (aspiration is a key risk)
  3. Stay with them and reassure calmly; keep the environment quiet
  4. If breathing is slow/shallow or they are unresponsive, call emergency services
  5. Do not let them wander; do not leave them alone
  6. Be ready to give rescue breaths / CPR

Effects wear off with time in a safe, monitored setting. The main dangers are physical injury and aspiration while incapacitated, and respiratory depression when combined with other depressants — not the dissociation itself.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Wallach J, Brandt SD (2018) 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_148
  2. [2]
    ^WHO Expert Committee on Drug Dependence (ECDD) (2023) Critical Review Report: 2-Fluorodeschloroketamine — WHO 46th ECDD Link
  3. [3]
    ^Joseph D, Lesueur C, Zerizer F, Fenot A, Alvarez JC (2023) Characterization of extensive 2-fluorodeschloroketamine metabolism in pooled human liver microsomes, urine and hair from an addicted patient — Journal of Analytical Toxicology doi:10.1093/jat/bkad030
  4. [4]
    ^Riess S, Chèze M, Muckensturm A, Klinger N, Roussel O, Cirimele V (2024) 2-Fluorodeschloroketamine consumption: About two deaths and a case of self-mutilation — Journal of Analytical Toxicology doi:10.1093/jat/bkae021
  5. [5]
    ^Gicquel T, Richeval C, Mesli V, Gish A, Hakim F, Pelletier R, Cornez R, Balgairies A, Allorge D, Gaulier JM (2021) Fatal intoxication related to two new arylcyclohexylamine derivatives (2F-DCK and 3-MeO-PCE) — Forensic Science International doi:10.1016/j.forsciint.2021.110852
Print version
Report an issue